SK bioscience Lands First UNICEF Influenza Vaccine Contract
Event summary
- SK bioscience secured its first UNICEF procurement contract for influenza vaccines, supplying 640,000 doses across Southern and Northern Hemisphere countries in 2026.
- The company is the sole supplier for the Southern Hemisphere and a major supplier for the Northern Hemisphere, enhancing its global public procurement footprint.
- SK bioscience's SKYCellflu vaccine, the world's first cell culture-based influenza vaccine with WHO Prequalification, will be used in countries like Laos, Myanmar, Fiji, Ethiopia, Lebanon, Albania, and Palestine.
- The contract marks SK bioscience's first collaboration with UNICEF, expanding its public procurement presence beyond its existing relationship with PAHO.
The big picture
SK bioscience's UNICEF contract solidifies its position in the global public procurement market, complementing its existing PAHO relationship. The deal underscores the growing importance of cell culture-based vaccines in enhancing immunogenicity and production efficiency. This strategic move aligns with broader industry trends toward sustainable revenue models that balance commercial growth with public health value.
What we're watching
- Execution Risk
- Whether SK bioscience can sustain operational efficiency and meet seasonal demand across diverse regions.
- Market Expansion
- The pace at which SK bioscience can secure additional public procurement contracts with international organizations.
- Regulatory Dynamics
- How global regulatory approvals for SK bioscience's vaccine portfolio will impact its market reach.
Related topics